Successful triple combination therapy of disseminated Absidia corymbifera infection in an adolescent with osteosarcoma

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 2, 2010, Pages 131-133

  Roux, Bénédicte Gaillard Le ^a   Méchinaud, Françoise ^a   Gay Andrieu, Françoise ^b   Lortholary, Olivier ^c,d   Dannaoui, Eric ^d,e   Hoinard, Damien ^e   Corradini, Nadege ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PASTEUR   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Absidia corymbifera fungal infection; Bone tumor; Mucormycosis; Neutropenia; Treatment morbidity; Zygomycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; POSACONAZOLE;

ABSIDIA; ADOLESCENT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CASE REPORT; CAST APPLICATION; DEBRIDEMENT; DRUG MEGADOSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEMUR FRACTURE; FUNGUS ISOLATION; HUMAN; HUMAN TISSUE; IMMOBILIZATION; INFECTION RISK; LUNG INFECTION; LUNG METASTASIS; MALNUTRITION; MUCORMYCOSIS; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PATHOLOGIC FRACTURE; PRIMARY TUMOR; PRIORITY JOURNAL; SKELETON TRACTION; SKIN INFECTION; VEIN THROMBOSIS;

EID: 77949456663     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ca0dcf     Document Type: Article

References (20)

1. ChayakulkeereeM, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25:215-229
2. Le Deley MC, Guinebretière JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752-761
3. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653
4. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39:425-429
5. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol. 2007;78:275-282
6. Tiong WH, Ismael T, McCann J. Post-traumatic and postsurgical Absidia corymbifera infection in a young, healthy man. J Plast Reconstr Aesthet Surg. 2006;59:1367-1371
7. Scalise A, Barchiesi F, Viviani MA, et al. Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot. J Infect. 1999;38:191-192
8. Christiaens G, Hayette MP, Jacquemin D, et al. An outbreak of Absidia corymbifera infection associated with bandage contamination in a burns unit. J Hosp Infect. 2005;61:88
9. Cantatore-Francis JL, Shin HT, Heilman E, et al. Primary cutaneous zygomycosis in two immunocompromised children. Pediatr Dermatol. 2007;24:257-262
10. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556-569
11. Dannaoui E, Mouton JW, Meis JF, et al. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother. 2002;46:1953-1959
12. Cagatay AA, Oncu SS, Calangu SS, et al. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis. 2001;1:22
13. Cornely OA, Vehreschild JJ, Ullmann AJ. Is there a role for polyenes in treating invasive mycoses? Curr Opin Infect Dis. 2006;19:565-570
14. Dannaoui E, Meis JF, Loebenberg D, et al. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47:3647-3650
15. Greenberg RN, Mullane K, Van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126-133
16. Van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61-e65
17. Page RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy. 2007;27:290-298
18. Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono- or combination therapy for the treatment of murine zygomycosis. Antimicrob Agents Chemother. 2009;53: 772-775
19. Spellberg B, Fu Y, Edwards JE, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830-832
20. Vazquez L, Mateos JJ, Sanz-Rodriguez C, et al. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica. 2005;90(12 suppl):ECR39